Hydromorphone therapy

  • US 5,914,131 A
  • Filed: 09/22/1997
  • Issued: 06/22/1999
  • Est. Priority Date: 07/07/1994
  • Status: Expired due to Term
First Claim
Patent Images

1. A dosage form comprising a drug layer comprising 8 mg of hydromorphone, 67.8 mg of poly(ethylene oxide) of 200,000 molecular weight, 4 mg of poly(vinyl pyrrolidone), and 0.2 mg of a lubricant;

  • a delivery layer comprising 37.8 mg of poly(ethylene oxide) possessing a 2,000,000 molecular weight, 18 mg of sodium chloride, 3 mg of hydroxypropylmethyl) cellulose of 9,200 molecular weight, 0.6 mg of a colorant, and 0.15 mg of a lubricant;

    a semipermeable wall comprising 27.2 mg of cellulose acetate of 39.8% acetyl content, and 0.275 mg of polyethylene glycol of 3,350 molecular weight;

    a passageway in the wall; and

    a controlled rate of release of 0.427 mg/hr for 17.3 hours.

View all claims
    ×
    ×

    Thank you for your feedback

    ×
    ×